Data / Drug companies / Solaris Pharma Corporation
Solaris Pharma Corporation: 20 products in the FDA NDC directory, labeler code 73473
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Solaris Pharma Corporation (labeler code 73473) lists 20 products in the FDA National Drug Code Directory, covering 11 finished drugs by generic name. By type: 20 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on February 4, 2026.
The request: Watch Solaris Pharma Corporation (FDA labeler code 73473): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 73473
- Products in commercial distribution
- 20
- Packages
- 26
- Finished drugs by generic name
- 11
- Prescription products
- 20
- Over the counter products
- 0
- Controlled substance products
- Schedule V 5
- Flagged as original packager
- 20 of 20 products that carry the flag
- Started marketing in the last 12 months
- 9
- Earliest marketing start
- September 10, 2019
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 20 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 20 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Brivaracetam | 5 | 17 |
| Clarithromycin | 3 | 27 |
| Tazarotene | 2 | 10 |
| Dicyclomine hydrochloride | 2 | 50 |
| Clindamycin phosphate | 2 | 31 |
| Clindamycin phosphate and tretinoin | 1 | 4 |
| Estradiol | 1 | 53 |
| Nitroglycerin | 1 | 40 |
| Neomycin sulfate | 1 | 12 |
| Metronidazole | 1 | 68 |
| Moxifloxacin hydrochloride | 1 | 20 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 8 | 40% |
| Gel | 7 | 35% |
| Tablet | 2 | 10% |
| Tablet, film coated, extended release | 1 | 5% |
| Capsule | 1 | 5% |
| Ointment | 1 | 5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Brivaracetam | 73473-908 | Tablet, film coated | Generic drugs (ANDA) | February 4, 2026 |
| Brivaracetam | 73473-907 | Tablet, film coated | Generic drugs (ANDA) | February 4, 2026 |
| Brivaracetam | 73473-906 | Tablet, film coated | Generic drugs (ANDA) | February 4, 2026 |
| Brivaracetam | 73473-905 | Tablet, film coated | Generic drugs (ANDA) | February 4, 2026 |
| Brivaracetam | 73473-904 | Tablet, film coated | Generic drugs (ANDA) | February 4, 2026 |
| Estradiol | 73473-308 | Gel | Generic drugs (ANDA) | January 28, 2026 |
| Nitroglycerin | 73473-500 | Ointment | Generic drugs (ANDA) | January 8, 2026 |
| Metronidazole | 73473-303 | Gel | Generic drugs (ANDA) | January 8, 2026 |
| Moxifloxacin | 73473-903 | Tablet, film coated | Generic drugs (ANDA) | December 12, 2025 |
| Dicyclomine hydrochloride | 73473-902 | Tablet | Generic drugs (ANDA) | June 10, 2025 |
| Dicyclomine hydrochloride | 73473-800 | Capsule | Generic drugs (ANDA) | June 10, 2025 |
| Tazarotene | 73473-310 | Gel | Generic drugs (ANDA) | January 3, 2025 |
| Tazarotene | 73473-309 | Gel | Generic drugs (ANDA) | January 3, 2025 |
| Clindamycin Phosphate and Tretinoin | 73473-306 | Gel | Generic drugs (ANDA) | January 3, 2025 |
| Clindamycin Phosphate | 73473-300 | Gel | Generic drugs (ANDA) | January 3, 2025 |
| Clindamycin Phosphate | 73473-302 | Gel | Generic drugs (ANDA) | September 15, 2024 |
| Neomycin Sulfate | 73473-901 | Tablet | Generic drugs (ANDA) | June 1, 2023 |
| Clarithromycin | 73473-910 | Tablet, film coated | Generic drugs (ANDA) | November 23, 2019 |
| Clarithromycin | 73473-909 | Tablet, film coated | Generic drugs (ANDA) | November 23, 2019 |
| Clarithromycin | 73473-911 | Tablet, film coated, extended release | Generic drugs (ANDA) | September 10, 2019 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.